VISTIN PHARMA ASA: årsregnskap 2023 vs 2022
Grew 44% on revenue, weaker earnings
approved 2024-04-23; registry 2024-08-08; journal 2024 637724
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for VISTIN PHARMA ASA. Revenue 304.9k NOK → 438.3k NOK (+43.8%). Net result -1.85m NOK → -2.98m NOK. Equity 268.13m NOK → 265.15m NOK.
On the constructive side: revenue rose; cash rose. Pressures included: operating result weakened; net result weakened; equity eroded.
Also worth watching: paid-in equity reduced; payroll increased; cogs fell. All figures are taken from the published annual accounts for VISTIN PHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 304.9k NOK to 438.3k NOK (+43.8% YoY). Calculated
-
↑
Cash rose
Bank deposits 1.39m NOK → 1.85m NOK (+33.2% YoY). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -4.19m NOK → -6.98m NOK (op. margin -1375.7% → -1592.0%). Calculated
-
↓
Net result weakened
Net result -1.85m NOK → -2.98m NOK (net margin -607.5% → -680.8%). Calculated
-
↓
Equity eroded
Book equity 268.13m NOK → 265.15m NOK (equity ratio 99.6% → 99.6%). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 268.13m NOK → 265.15m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 1.96m NOK → 2.15m NOK (644% → 490% of revenue). Calculated
-
·
COGS fell
COGS / varekostnad 138.06m NOK → 176.6k NOK (-99.9% YoY). Calculated
-
·
Book investments changed
Investment / intangible book value 108.1k NOK → 113.1k NOK. Reported fact